Hims(US:HIMS) Prnewswireยท2025-07-10 20:06Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3] Group 1: Company Actions and Allegations - Hims & Hers is accused of making materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk during the class period from April 29, 2025, to June 22, 2025 [3] - The termination of the partnership with Novo Nordisk led to a significant decline in Hims & Hers' stock price, dropping over 34% in intraday trading, indicating investor concerns about regulatory compliance and reputational risks [2] Group 2: Legal Proceedings - Berger Montague is investigating potential securities fraud claims against Hims & Hers, with a deadline for investors to seek lead plaintiff status by August 25, 2025 [1] - The investigation focuses on whether Hims & Hers and certain executives violated federal securities laws by providing false or misleading information to investors [3]